ASP Isotopes provides $5M seed funding to IsoBio for cancer radiotherapeutics

ASP Isotopes Inc.

IsoBio closed initial Series Seed round, raising $5 million from ASP Isotopes (ASPI).
IsoBio will develop antibody-isotope conjugates (AICs) using Lutetium-177, Actinium-225, Terbium-161, and other novel isotopes.
IsoBio is co-founded and led by CEO Bruce Turner, M.D., Ph.D., former Immunome co-lead; offices in Seattle and Gladwyne, PA.
Strategic collaboration includes future manufacturing opportunities with ASPI's nuclear medicine subsidiary PET Labs.
Investor webcast to discuss collaboration on July 30, 2025 at 10:00 AM Eastern.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.